ARS Pharma shares are trading lower after the FDA issued a Complete Response Letter for the company's neffy epinephrine nasal spray, with request for additional study.
Portfolio Pulse from Benzinga Newsdesk
ARS Pharma's shares are trading lower following the FDA's Complete Response Letter for the company's neffy epinephrine nasal spray, requesting additional study.
September 20, 2023 | 11:51 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ARS Pharma's stock is trading lower due to the FDA's request for additional study on its neffy epinephrine nasal spray.
The FDA's request for additional study on ARS Pharma's product implies potential regulatory hurdles, which can negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100